Biomarkers for Microglial Activation in Alzheimer's Disease

Biomarkers for Microglial Activation in Alzheimer's Disease

Intensive research over the last decades has provided increasing evidence for neuroinflammation as an integral part in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD). Inflammatory responses in the central nervous system (CNS) are initiated by activated microglia...

Full description

Bibliographic Details
Main Authors:	Lautner, Ronald, Mattsson, Niklas, Schöll, Michael, Augutis, Kristin, Blennow, Kaj, Olsson, Bob, Zetterberg, Henrik
Format:	Online
Language:	English
Published:	SAGE-Hindawi Access to Research 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206374/

Similar Items

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
by: Palmqvist, Sebastian, et al.
Published: (2015)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
by: Skillbäck, Tobias, et al.
Published: (2013)

Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease
by: Armstrong, Andrea, et al.
Published: (2013)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
by: Blennow, Kaj, et al.
Published: (2015)

Fluid biomarkers in Alzheimer’s disease – current concepts
by: Rosén, Christoffer, et al.
Published: (2013)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
by: Mattsson, Niklas, et al.
Published: (2016)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
by: Stomrud, Erik, et al.
Published: (2015)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
by: Cicognola, Claudia, et al.
Published: (2016)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
by: Janelidze, Shorena, et al.
Published: (2015)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
by: Hölttä, Mikko, et al.
Published: (2013)

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4
by: Andreasson, U, et al.
Published: (2014)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
by: Andreasson, Ulf, et al.
Published: (2016)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
by: Mattsson, Niklas, et al.
Published: (2014)

Plasma tau levels in Alzheimer's disease
by: Zetterberg, Henrik, et al.
Published: (2013)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
by: Johansson, Per, et al.
Published: (2013)

Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.
by: Per Johansson, et al.

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
by: Palmqvist, Sebastian, et al.
Published: (2012)

Plasma tau in Alzheimer disease
by: Mattsson, Niklas, et al.
Published: (2016)

Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease
by: Öhrfelt, Annika, et al.
Published: (2011)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
by: Piotr Lewczuk, et al.
Published: (2018-07-01)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
by: Öhrfelt, Annika, et al.
Published: (2016)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
by: Hölttä, Mikko, et al.
Published: (2012)

Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
by: Bremell, Daniel, et al.
Published: (2013)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
by: Hall, Sara, et al.
Published: (2016)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
by: Janelidze, Shorena, et al.
Published: (2016)

Levels of ADAM10 are reduced in Alzheimer’s disease CSF
by: Aitana Sogorb-Esteve, et al.
Published: (2018-07-01)

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease
by: Öhrfelt, Annika, et al.
Published: (2016)

Importance of GPCR-Mediated Microglial Activation in Alzheimer’s Disease
by: Md. Ezazul Haque, et al.
Published: (2018-08-01)

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
by: Meredith Jr., Jere E., et al.
Published: (2013)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
by: Brinkmalm, Ann, et al.
Published: (2014)

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease
by: Rosén, Christoffer, et al.
Published: (2014)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
by: Janelidze, Shorena, et al.
Published: (2016)

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage
by: Portelius, Erik, et al.
Published: (2014)

Genetic Variants and Related Biomarkers in Sporadic Alzheimer’s Disease
by: Guerreiro, Rita, et al.
Published: (2014)

Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke
by: Hjalmarsson, Clara, et al.
Published: (2014)

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
by: Mattsson, Niklas, et al.
Published: (2016)

CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma
by: Neselius, Sanna, et al.
Published: (2012)

Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers
by: Neselius, Sanna, et al.
Published: (2014)

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
by: Sjödin, Simon, et al.
Published: (2015)

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
by: Insel, Philip S, et al.
Published: (2015)